EyePoint Pharmaceuticals announced it has completed patient enrollment in its two ongoing phase 3 clinical trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD).
According to the company, the studies—named DURAVYU-01 and DURAVYU-02—have each enrolled approximately 300 patients across sites in the United States and Canada. The primary objective is to compare Duravyu, a sustained-release formulation of vorolanib, to standard intravitreal anti-VEGF therapy in patients with wet AMD.
The company said that Duravyu is designed to reduce the treatment burden associated with frequent eye injections, aiming to provide up to six months of efficacy from a single administration. EyePoint claims that this could address a significant unmet need for patients and caregivers by improving compliance and maintaining vision outcomes.
Top-line data from both trials are expected in the second half of 2026, with the company indicating that positive results could support a potential regulatory submission to the U.S. Food and Drug Administration.
EyePoint added that the completion of enrollment marks a key milestone in its clinical program and aligns with its broader strategy to advance innovative ophthalmic products. The company also noted its commitment to addressing chronic eye diseases through sustained delivery technologies.
According to EyePoint, if successful, Duravyu could become an important alternative to current treatment options for wet AMD, which affects millions worldwide.
